Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGEarly Phase 1INTERVENTIONAL

Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The goal of this study is to learn if a suprachoroidal triamcinolone injection can treat vision-threatening swelling in the center of the retina (macular edema) caused by non-infectious uveitis, especially in people who did not improve after a standard steroid injection around the eye (sub-Tenon injection). The main questions it aims to answer are: Does vision improve on the eye chart after the injection? Does the injection lower retinal swelling (reduction in thickness) within 3 months? Participants will: Have a pre-treatment check (vision test, slit-lamp exam, and a retinal scan called OCT). Receive one suprachoroidal triamcinolone injection under anesthetics drops in a sterile setting (operating room) with standard monitoring. Return for visits about 1 month and 3 months after treatment for repeat vision tests, and OCT scans. Contact the clinic if they notice pain, redness, new floaters, or worsening vision.

Who May Be Eligible (Plain English)

Who May Qualify: - Non-infectious uveitis complicated with macular edema - Uveitic macular edema of less than four months' duration - Macular edema persisted despite lack of intra-ocular inflammation - No response to posterior sub-Tenon triamcinolone acetonide injections Who Should NOT Join This Trial: - Those with epiretinal membrane-associated macular edema - Below 18 years Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Non-infectious uveitis complicated with macular edema * Uveitic macular edema of less than four months' duration * Macular edema persisted despite lack of intra-ocular inflammation * No response to posterior sub-Tenon triamcinolone acetonide injections Exclusion Criteria: * Those with epiretinal membrane-associated macular edema * Below 18 years

Treatments Being Tested

DRUG

Suprachoroidal triamcinolone acetonide injection

For suprachoroidal injection, we developed a custom-made delivery system to access the potential suprachoroidal space. A 1 mL tuberculin syringe fitted with a 27-gauge needle was prepared, and a plastic sleeve from a 24-26 G IV cannula was placed over the needle as a spacer to control penetration depth.

Locations (1)

Ibn Al-Haitham Eye Teaching Hospital
Baghdad, Iraq